Pasithea Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.pasithea.com
- Introduction
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
- Conditions
- NF1 MutationNeurofibroma, PlexiformNeurofibroma PlexiformNeurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)Neurofibromatosis Type 1 (NF1)
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Pasithea Therapeutics Corp.
- Target Recruit Count
- 56
- Registration Number
- NCT06961565
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
PAS-004 in Patients With Advanced Solid Tumors
- Conditions
- RAS MutationNF1 MutationRAF MutationAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Pasithea Therapeutics Corp.
- Target Recruit Count
- 48
- Registration Number
- NCT06299839
- Locations
- 🇺🇸
NEXT Oncology, Fairfax, Virginia, United States
🇧🇬MBAL Sveta Sofia, Sofia, Bulgaria
🇷🇴Institute of Oncology Bucharest Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania
News
Neurofibromatoses Pipeline Shows Strong Activity with 12+ Therapies in Development Across Multiple Clinical Stages
DelveInsight's 2025 pipeline report reveals over 10 pharmaceutical companies are actively developing 12+ therapies for neurofibromatoses treatment across various clinical stages.